Celyad Oncology S.A. (CYAD)’in fiyatı nedir?

Celyad Oncology S.A. (CYAD)’in fiyatı $0.343985’dir

Celyad Oncology S.A. (CYAD)’in piyasa değeri nedir?

Celyad Oncology S.A. (CYAD)’in piyasa değeri $15.40M’dir.

Celyad Oncology S.A. (CYAD) Tedavüldeki Hisseler

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.

Yıl	Tedavüldeki Hisse Sayısı	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Tedavüldeki Hisse Sayısı

Değiştir

Sağlanan tarihler için yeterli veri yok.

Şirket	Tedavüldeki Hisse Sayısı	Fark	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	483.58M	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	0.00	-	BE

Şirket

Tedavüldeki Hisse Sayısı

Fark

Ülke